建禹集團(08196.HK)前三季度虧損減少約38.6%至1064萬元
格隆匯11月9日丨建禹集團(08196.HK)公佈,截至2021年9月30日止9個月,公司收益為約人民幣6533萬元,較2020年同期增加約77.9%;公司普通權益持有人應占虧損為約人民幣1064萬元,較2020年同期普通權益持有人應占虧損減少約38.6%。
虧損減少乃主要由於(1)集團於截至2021年9月30日止九個月的毛利較2020年同期上升,此乃由於集團承接毛利率高的技術諮詢項目;(2)集團截至2021年9月30日止九個月主要來自設備項目及服務特許經營安排分部的收益較2020年同期增加;及(3)並無產生於2020年同期因提升集團建設資格而產生的開支約人民幣300萬元所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.